Literature DB >> 35293781

Klebsiella pneumoniae Mutants Resistant to Ceftazidime-Avibactam Plus Aztreonam, Imipenem-Relebactam, Meropenem-Vaborbactam, and Cefepime-Taniborbactam.

Naphat Satapoomin1, Punyawee Dulyayangkul1, Matthew B Avison1.   

Abstract

We show that a previously described Klebsiella pneumoniae variant that is resistant to ceftazidime-avibactam plus meropenem-vaborbactam, has a ramR plus ompK36 mutation, and produces the V239G variant KPC-3 (V240G per the standard numbering system) exhibits resistance to ceftazidime-avibactam plus aztreonam and imipenem-relebactam but not cefepime-taniborbactam. The V239G variant does not generate collateral β-lactam susceptibility like many KPC-3 variants associated with ceftazidime-avibactam resistance. Additional mutation of ompK35 and production of the OXA-48-like carbapenemase OXA-232 were required to confer cefepime-taniborbactam resistance.

Entities:  

Keywords:  KPC; carbapenemase

Mesh:

Substances:

Year:  2022        PMID: 35293781      PMCID: PMC9017312          DOI: 10.1128/aac.02179-21

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.938


  17 in total

1.  Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A beta-lactamase, KPC-3, in a New York Medical Center.

Authors:  Neil Woodford; Philip M Tierno; Katherine Young; Luke Tysall; Marie-France I Palepou; Elaina Ward; Ronald E Painter; Deborah F Suber; Daniel Shungu; Lynn L Silver; Kenneth Inglima; John Kornblum; David M Livermore
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

2.  Resistance to Ceftazidime/Avibactam plus Meropenem/Vaborbactam When Both Are Used Together Is Achieved in Four Steps in Metallo-β-Lactamase-Negative Klebsiella pneumoniae.

Authors:  Punyawee Dulyayangkul; Edward J A Douglas; Filip Lastovka; Matthew B Avison
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

3.  Reduced Susceptibility to Cefepime in Clinical Isolates of Enterobacteriaceae Producing OXA-1 Beta-Lactamase.

Authors:  Eva Torres; Lorena López-Cerero; José Manuel Rodríguez-Martínez; Álvaro Pascual
Journal:  Microb Drug Resist       Date:  2015-08-21       Impact factor: 3.431

4.  In vitro selection of aztreonam/avibactam resistance in dual-carbapenemase-producing Klebsiella pneumoniae.

Authors:  Siqiang Niu; Jie Wei; Chunhong Zou; Kalyan D Chavda; Jingnan Lv; Haifang Zhang; Hong Du; Yi-Wei Tang; Johann D D Pitout; Robert A Bonomo; Barry N Kreiswirth; Liang Chen
Journal:  J Antimicrob Chemother       Date:  2020-03-01       Impact factor: 5.790

5.  Effect of Porins and blaKPC Expression on Activity of Imipenem with Relebactam in Klebsiella pneumoniae: Can Antibiotic Combinations Overcome Resistance?

Authors:  Gregory Balabanian; Michael Rose; Nyla Manning; David Landman; John Quale
Journal:  Microb Drug Resist       Date:  2018-05-21       Impact factor: 3.431

6.  Impaired Inhibition by Avibactam and Resistance to the Ceftazidime-Avibactam Combination Due to the D179Y Substitution in the KPC-2 β-Lactamase.

Authors:  Fabrice Compain; Michel Arthur
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

7.  Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.

Authors:  Mariana Castanheira; Timothy B Doyle; Lalitagauri M Deshpande; Rodrigo E Mendes; Helio S Sader
Journal:  Int J Antimicrob Agents       Date:  2021-09-20       Impact factor: 5.283

Review 8.  Interplay between β-lactamases and new β-lactamase inhibitors.

Authors:  Karen Bush; Patricia A Bradford
Journal:  Nat Rev Microbiol       Date:  2019-05       Impact factor: 60.633

9.  VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa.

Authors:  Jodie C Hamrick; Jean-Denis Docquier; Tsuyoshi Uehara; Cullen L Myers; David A Six; Cassandra L Chatwin; Kaitlyn J John; Salvador F Vernacchio; Susan M Cusick; Robert E L Trout; Cecilia Pozzi; Filomena De Luca; Manuela Benvenuti; Stefano Mangani; Bin Liu; Randy W Jackson; Greg Moeck; Luigi Xerri; Christopher J Burns; Daniel C Pevear; Denis M Daigle
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

10.  Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019.

Authors:  Rodrigo E Mendes; Timothy B Doyle; Jennifer M Streit; Francis F Arhin; Helio S Sader; Mariana Castanheira
Journal:  J Antimicrob Chemother       Date:  2021-10-11       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.